Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Sohini Mondal

THE TRUTH ABOUT: Charles river laboratories q3 2024 earnings what to expect | History Defined

With a market cap of $9.4 billion, Wilmington, Massachusetts-based Charles River Laboratories International, Inc. (CRL) is a leading contract research organization (CRO) in the healthcare sector. It offers a wide range of services, including research models, safety assessments, and manufacturing support to facilitate drug development for pharmaceutical and biotechnology clients globally. CRL is expected to release its fiscal Q3 earnings results before the market opens on Wednesday, Nov. 6.

Ahead of this event, analysts expect the contract drug developer to report a profit of $2.43 per share, down 10.7% from $2.72 per share in the year-ago quarter. However, the company has surpassed Wall Street's bottom-line estimates in the last four quarters. CRL exceeded the consensus EPS estimate by 17.2% in the most recent quarter.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.